Novo Nordisk’s oral Wegovy outperforms projections, potentially reversing the stock’s 40% three-year decline amid GLP-1 market competition.
Novo Nordisk’s Wegovy pill has exceeded market expectations, offering a potential turnaround for its stock after a 40% drop over the past three years. The oral version addresses consumer preference over injectable alternatives, boosting its competitive stance in the GLP-1 weight-loss drug sector.
The company initially led the market with its Wegovy shot but struggled with supply constraints, allowing Eli Lilly’s Mounjaro and Zepbound to gain dominance. Eli Lilly’s drugs also demonstrated higher efficacy, contributing to its 150% stock surge over the same period.
The introduction of the Wegovy pill in early 2026 could shift investor sentiment, particularly among dividend-focused buyers, as Novo Nordisk aims to reclaim market share.